SNJ-1945, a calpain inhibitor, protects SH-SY5Y cells against MPP + and rotenone

Journal of Neurochemistry

Volumn 130, Issue 2, 2014, Pages 280-290

  Knaryan, Varduhi H ^a   Samantaray, Supriti ^a   Park, Sookyoung ^a   Azuma, Mitsuyoshi ^b   Inoue, Jun ^b   Banik, Naren L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b SENJU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

calpain; cell viability; experimental parkinsonism; inflammation; neuroprotection; oxidative stress

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CALPAIN; CALPASTATIN; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA CONVERTING ENZYME; REACTIVE OXYGEN METABOLITE; ROTENONE; [1 [(1 BENZYL 3 CYCLOPROPYLAMINO 2,3 DIOXOPROPYL)CARBAMOYL] 3 METHYLBUTYL]CARBAMIC ACID 2 (2 METHOXYETHOXY)ETHYL ESTER;

ARTICLE; CALCIUM CELL LEVEL; CELL DIFFERENTIATION; CELL LINE; CELL PROTECTION; CELL STRUCTURE; CELL VIABILITY; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NEUROBLASTOMA CELL LINE; NEUROPROTECTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SH SY5Y CELL;

PARKINSONIA;

CALPAIN; CELL VIABILITY; EXPERIMENTAL PARKINSONISM; INFLAMMATION; NEUROPROTECTION; OXIDATIVE STRESS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; BLOTTING, WESTERN; CALCIUM; CALPAIN; CARBAMATES; CELL LINE, TUMOR; CELL SURVIVAL; CYSTEINE PROTEINASE INHIBITORS; DOPAMINE AGENTS; ENZYME ACTIVATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INFLAMMATION MEDIATORS; NEUROPROTECTIVE AGENTS; REACTIVE OXYGEN SPECIES; ROTENONE; UNCOUPLING AGENTS;

EID: 84904063203     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12629     Document Type: Article

References (44)

1. Bains M., Cebak J. E., Gilmer L. K., Barnes C. C., Thompson S. N., Geddes J. W., and, Hall E. D., (2013) Pharmacological analysis of the cortical neuronal cytoskeletal protective efficacy of the calpain inhibitor SNJ-1945 in a mouse traumatic brain injury model. J. Neurochem. 125, 125-132.
2. Banerjee R., Starkov A. A., Beal M. F., and, Thomas B., (2009) Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim. Biophys. Acta 1792, 651-663.
3. Banik N. L., Hogan E. L., Jenkins M. G., McDonald J. K., McAlhaney W. W., and, Sostek M. B., (1983) Purification of a calcium-activated neutral proteinase from bovine brain. Neurochem. Res. 8, 1389-1405. (Pubitemid 14200496)
4. Braak H., Sastre M., Bohl J. R., de Vos R. A., and, Del Tredici K., (2007) Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 113, 421-429. (Pubitemid 46421631)
5. Cheng Y. F., Zhu G. Q., Wang M., et al,. (2009) Involvement of ubiquitin proteasome system in protective mechanisms of Puerarin to MPP(+)-elicited apoptosis. Neurosci. Res. 63, 52-58.
6. Chera B., Schaecher K. E., Rocchini A., Imam S. Z., Ray S. K., Ali S. F., and, Banik N. L., (2002) Calpain upregulation and neuron death in spinal cord of MPTP-induced parkinsonism in mice. Ann. N. Y. Acad. Sci. 965, 274-280. (Pubitemid 34721975)
7. Chera B., Schaecher K. E., Rocchini A., Imam S. Z., Sribnick E. A., Ray S. K., Ali S. F., and, Banik N. L., (2004) Immunofluorescent labeling of increased calpain expression and neuronal death in the spinal cord of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. Brain Res. 1006, 150-156. (Pubitemid 38393759)
8. Crocker S. J., Smith P. D., Jackson-Lewis V., et al,. (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci. 23, 4081-4091. (Pubitemid 36958427)
9. Del Tredici K., and, Braak H., (2012) Spinal cord lesions in sporadic Parkinson's disease. Acta Neuropathol. 124, 643-664.
10. Esteves A. R., Arduino D. M., Swerdlow R. H., Oliveira C. R., and, Cardoso S. M., (2010) Dysfunctional mitochondria uphold calpain activation: contribution to Parkinson's disease pathology. Neurobiol. Dis. 37, 723-730.
11. Giza E., Gotzamani-Psarrakou A., and, Bostantjopoulou S., (2012) Imaging beyond the striatonigral dopaminergic system in Parkinson's disease. Hell. J. Nucl. Med. 15, 224-232.
12. Glass C. K., Saijo K., Winner B., Marchetto M. C., and, Gage F. H., (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
13. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260, 3440-3450. (Pubitemid 15114340)
14. Hornykiewicz O., (2008) Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Neurodegener. Dis. 5, 114-117. (Pubitemid 351347826)
15. Jun-ichi K., (2013) Neuroinflammation in Neurological Disorders, Vol. Advances in Neurobiology: Neuron-Glia Interaction in Neuroinflammation. Springer, New York.
16. Knaryan V. H., Samantaray S., Le Gal C., Ray S. K., and, Banik N. L., (2011) Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies. J. Neurochem. 118, 326-338.
17. Koumura A., Nonaka Y., Hyakkoku K., Oka T., Shimazawa M., Hozumi I., Inuzuka T., and, Hara H., (2008) A novel calpain inhibitor, ((1S)-1((((1S)-1- benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-met hylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester, protects neuronal cells from cerebral ischemia-induced damage in mice. Neuroscience 157, 309-318.
18. Ma H., Tochigi A., Shearer T. R., and, Azuma M., (2009) Calpain inhibitor SNJ-1945 attenuates events prior to angiogenesis in cultured human retinal endothelial cells. J. Ocul. Pharmacol. Ther. 25, 409-414.
19. Martins J. B., Bastos Mde L., Carvalho F., and, Capela J. P., (2013) Differential effects of methyl-4-phenylpyridinium ion, rotenone, and paraquat on differentiated SH-SY5Y cells. J. Toxicol. 2013, 347312.
20. Mastroeni D., Grover A., Leonard B., Joyce J. N., Coleman P. D., Kozik B., Bellinger D. L., and, Rogers J., (2009) Microglial responses to dopamine in a cell culture model of Parkinson's disease. Neurobiol. Aging 30, 1805-1817.
21. Mouatt-Prigent A., Karlsson J. O., Yelnik J., Agid Y., and, Hirsch E. C., (2000) Calpastatin immunoreactivity in the monkey and human brain of control subjects and patients with Parkinson's disease. J. Comp. Neurol. 419, 175-192. (Pubitemid 30133500)
22. Olanow C. W., Stocchi F., and, Lang A. E., (2011) Parkinson's Disease: Non-Motor and Non-Dopaminergic Features. Wiley-Blackwell, Chichester, UK.
23. Presgraves S. P., Ahmed T., Borwege S., and, Joyce J. N., (2004a) Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox. Res. 5, 579-598.
24. Presgraves S. P., Borwege S., Millan M. J., and, Joyce J. N., (2004b) Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. Exp. Neurol. 190, 157-170. (Pubitemid 39335715)
25. Ray S. K., Wilford G. G., Ali S. F., and, Banik N. L., (2000) Calpain upregulation in spinal cords of mice with 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced Parkinson's disease. Ann. N. Y. Acad. Sci. 914, 275-283.
26. Roy A., Ghosh A., Jana A., Liu X., Brahmachari S., Gendelman H. E., and, Pahan K., (2012) Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS ONE 7, e38113.
27. Samantaray S., Knaryan V. H., Guyton M. K., Matzelle D. D., Ray S. K., and, Banik N. L., (2007) The parkinsonian neurotoxin rotenone activates calpain and caspase-3 leading to motoneuron degeneration in spinal cord of Lewis rats. Neuroscience 146, 741-755. (Pubitemid 46656209)
28. Samantaray S., Knaryan V. H., Butler J. T., Ray S. K., and, Banik N. L., (2008a) Spinal cord degeneration in C57BL/6N mice following induction of experimental parkinsonism with MPTP. J. Neurochem. 104, 1309-1320. (Pubitemid 351293347)
29. Samantaray S., Ray S. K., and, Banik N. L., (2008b) Calpain as a potential therapeutic target in Parkinson's disease. CNS Neurol. Disord. Drug Targets 7, 305-312.
30. Samantaray S., Knaryan V. H., Le Gal C., Ray S. K., and, Banik N. L., (2011) Calpain inhibition protected spinal cord motoneurons against 1-methyl-4-phenylpyridinium ion and rotenone. Neuroscience 192, 263-274.
31. Samantaray S., Knaryan V. H., Shields D. C., and, Banik N. L,. (2013a) Critical role of calpain in spinal cord degeneration in Parkinson's disease. J. Neurochem. 127, 880-890.
32. Samantaray S., Knaryan V. H., Shields D. C., and, Banik N. L., (2013b) Possible calpain-mediated spinal cord degeneration of Parkinson's disease. J. Neurochem. 125 (Suppl. 1), 141.
33. Shanab A. Y., Nakazawa T., Ryu M., et al,. (2012) Metabolic stress response implicated in diabetic retinopathy: the role of calpain, and the therapeutic impact of calpain inhibitor. Neurobiol. Dis. 48, 556-567.
34. Shields D. C., and, Banik N. L., (1998) Upregulation of calpain activity and expression in experimental allergic encephalomyelitis: a putative role for calpain in demyelination. Brain Res. 794, 68-74. (Pubitemid 28298866)
35. Shields D. C., Schaecher K. E., Saido T. C., and, Banik N. L., (1999) A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc. Natl Acad. Sci. USA 96, 11486-11491. (Pubitemid 29487407)
36. Shimazawa M., Suemori S., Inokuchi Y., Matsunaga N., Nakajima Y., Oka T., Yamamoto T., and, Hara H., (2010) A novel calpain inhibitor, ((1S)-1-((((1S)-1-Benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl) -3-me thylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester (SNJ-1945), reduces murine retinal cell death in vitro and in vivo. J. Pharmacol. Exp. Ther. 332, 380-387.
37. Takeshita D., Tanaka M., Mitsuyama S., Yoshikawa Y., Zhang G. X., Obata K., Ito H., Taniguchi S., and, Takaki M., (2013) A new calpain inhibitor protects left ventricular dysfunction induced by mild ischemia-reperfusion in in situ rat hearts. J. Physiol. Sci. 63, 113-123.
38. Teismann P., Tieu K., Choi D. K., Wu D. C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and, Przedborski S., (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci. USA 100, 5473-5478. (Pubitemid 36542729)
39. Vijitruth R., Liu M., Choi D. Y., Nguyen X. V., Hunter R. L., and, Bing G., (2006) Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J. Neuroinflammation 3, 6.
40. Vivacqua G., Casini A., Vaccaro R., Salvi E. P., Pasquali L., Fornai F., Yu S., and, D'Este L., (2011) Spinal cord and parkinsonism: neuromorphological evidences in humans and experimental studies. J. Chem. Neuroanat. 42, 327-340.
41. Vivacqua G., Biagioni F., Yu S., Casini A., Bucci D., D'Este L., and, Fornai F., (2012) Loss of spinal motor neurons and alteration of alpha-synuclein immunostaining in MPTP induced Parkinsonism in mice. J. Chem. Neuroanat. 44, 76-85.
42. Wakabayashi K., and, Takahashi H., (1997) The intermediolateral nucleus and Clarke's column in Parkinson's disease. Acta Neuropathol. 94, 287-289. (Pubitemid 27395331)
43. Xie H. R., Hu L. S., and, Li G. Y., (2010) SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin. Med. J. 123, 1086-1092.
44. Yoshikawa Y., Zhang G. X., Obata K., Ohga Y., Matsuyoshi H., Taniguchi S., and, Takaki M., (2010) Cardioprotective effects of a novel calpain inhibitor SNJ-1945 for reperfusion injury after cardioplegic cardiac arrest. Am. J. Physiol. Heart Circ. Physiol. 298, H643-H651.